Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 1-1, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 10-10, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 101-101, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 103-103, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 105-105, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 106-106, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 107-107, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 108-108, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 109-109, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 11-11, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 110-110, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 111-111, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 112-112, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 113-113, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 114-114, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 115-115, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 116-116, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 118-118, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 119-119, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 120-120, July 2026.

Journal of Clinical Oncology, Volume 44, Issue 19_suppl, Page 121-121, July 2026.

Patients with shrinking cognitive bandwidth may feel their disability keenly in daily life, even if they can pass a controlled test of cognitive capacity. How should clinicians approach and care for them?

In a cluster-randomized trial involving patients having major noncardiac surgery, tranexamic acid reduced the need for red-cell transfusion during hospitalization and was noninferior to placebo for venous thromboembolism within 90 days.

Among 38 patients who received CAR T-cell therapy for refractory or relapsed B-cell lymphomas, lymphoma-free survival at 10 years was 32% for large B-cell lymphomas and 47% for follicular lymphoma.

Every year, many millions of surgical patients worldwide are unnecessarily exposed to a higher-than-necessary risk of blood transfusion because they do not receive a single dose of tranexamic acid just before the surgery. This failing is due not to a lack of high-quality scientific evidence on the overall safety, efficacy,...

The EPA has decided to stop considering the monetary value of public health benefits in federal rulemaking related to air pollution. This decision could have profound health consequences.

A rapid response to crizotinib after failure of chemotherapy in a patient with infantile fibrosarcoma with a TFG::MET fusion underscores the value of molecular profiling in atypical disease. This approach could enable limb sparing.

Among patients with traumatic hemorrhage, prehospital whole-blood transfusion was not superior to standard transfusion with red-cell and plasma components in reducing the risk of death or massive transfusion.

Among patients with moderate or severe PTS, the addition of endovascular therapy to standard care resulted in less severe PTS and better quality of life at 6 months than standard care alone but with a higher risk of bleeding.

Among patients with traumatic hemorrhage, prehospital transfusion of whole blood did not result in lower 30-day mortality than transfusion of plasma or red cells. Outcomes did not differ according to the storage age of blood.

This review of the evolving management of differentiated thyroid cancer highlights overdiagnosis of low-risk disease, dynamic risk stratification, active surveillance or ablation, targeted therapies, and active patient involvement.

A 74-year-old man with a recent orthotopic heart transplantation was admitted to the hospital because of persistent pancytopenia that resulted in serial transfusions of packed red cells. A diagnosis was made.

Post-thrombotic syndrome is the most common chronic complication of deep-vein thrombosis (DVT), affecting 20 to 50% of patients with DVT and causing debilitating symptoms involving the limbs — including pain, swelling, skin changes, and venous ulcers — that substantially reduce quality of life and impose considerable socioeconomic burden.1 ...

Hemorrhagic shock remains the leading cause of preventable death after injury.1 Over the past two decades, early administration of blood products has transformed care for patients with bleeding. The Pragmatic, Randomized Optimal Platelet and Plasma Ratios (PROPPR) trial2 established that among patients with severe trauma and...

The clinical benefits of checkpoint inhibitors in the treatment of cancer often wane. A preclinical study points to a potential strategy for a more durable effect.

A 66-year-old man with a history of Crohn’s disease treated with long-term adalimumab presented with fever and swelling of both knees. Analysis of a biopsy sample of the left knee synovium showed an atypical T-cell infiltrate.

In an African study of severe malaria in children with partially artemisinin-resistant parasites with PfK13 mutations, artesunate did not lead to worse outcomes, which suggests that parenteral artesunate may still be used.

In a phase 3, randomized trial of lonvo-z, an in vivo gene editing therapy, patients with hereditary angioedema who received the drug had a significantly lower attack rate than those who received placebo.

Talquetamab–daratumumab, with or without pomalidomide, led to longer progression-free survival than daratumumab-based standard care in relapsed or refractory myeloma. More than 75% of patients had grade 3 or higher adverse events.

The authors report the results of interim analyses of two phase 3 studies of exa-cel, a gene-edited cellular therapy, in children with transfusion-dependent β-thalassemia or sickle cell disease.

The authors review current strategies for anticoagulation reversal in major bleeding events or urgent surgery as well as specific antidotes, limits of available evidence, thrombotic risks, unmet therapeutic needs, and ongoing research.

Attending large scientific conferences can be an endurance test. The sunrise sessions, the multiple parallel tracks, the thousands of steps walking back-and-forth from one end of a convention centre to the other, and the evening receptions, all combined with meetings with colleagues, old and new. But occasionally, it becomes apparent that the conference in question is different, that something historic has happened. This year's American Society of Clinical Oncology (ASCO) annual meeting was one such occasion, evoking memories of other examples such as ASCO 2010 and the 2025 San Antonio Breast Cancer Symposium (SABCS).

The SUBITO trial, presented by Rianne L Seefat and colleagues in The Lancet Oncology,1 revisits the long-standing debate surrounding high-dose chemotherapy with autologous stem-cell rescue in patients with high-risk early breast cancer, exploring its potential role in the modern era of therapies targeted to homologous recombination-deficient (HRD) tumours.

Although oestrogen receptor, progesterone receptor, and HER2 receptor expression status help to tailor neoadjuvant systemic therapy regimens in patients with breast cancer, the response to treatment is arguably more prognostic than is receptor status itself. The amount of residual disease following neoadjuvant therapy, as calculated by the residual cancer burden index, correlates with disease recurrence independent of stage or receptor status.1 In patients with high risk of recurrence based on substantial residual disease, trials such as KATHERINE and CREATE-X provide data to support escalation of adjuvant systemic therapy, providing truly personalised medicine for patients with breast cancer.

A non-invasive diagnostic test that enables us to safely avoid an invasive test is valuable. Historically, an elevated prostate-specific antigen (PSA) was the primary driver for a prostate biopsy. This approach was refined as a result of multiple large trials demonstrating the benefit of an MRI-based triage system, with MRI generally increasing the detection of clinically significant prostate cancer while reducing prostate biopsies.1

In The Lancet Oncology, Frank A Giordano and colleagues report the outcome of the INTRAGO II trial, a randomised, phase 3 study investigating the benefit of radiotherapy dose intensification in 314 patients with glioblastoma. The authors must be congratulated for successfully completing a technically complex trial. The radiotherapy boost was given with an additional 30 Gy single dose of intraoperative radiation by use of low-energy x-rays emitting 50 kV photons to the resection cavity, in addition to standard-of-care chemoradiotherapy.

Pleural mesothelioma is an uncommon, asbestos-associated cancer. Unlike most primary tumours, which grow spherically, mesothelioma conforms to the complex shape of the pleural cavity. As the disease progresses, multifocal tumour nodules coalesce and thicken to produce a crescent-shaped rind encasing the lung. Tumour foci might invade into adjacent structures, with limited between-plane resolution on routine imaging. This morphological complexity, combined with a typical pleural surface area of around 4000 cm2, makes radiological quantification extremely challenging.

The National Cancer Plan for England, published in February, 2026, sets out ambitious plans for the future of cancer care in England over the next 10 years.1 Overlooked in the plan, however, is the need to align these plans with the legal commitment of the National Health Service (NHS) to developing an environmentally sustainable health-care system, reducing health care-associated greenhouse gas emissions to net zero by 2045.2 Many policies set out in the plan could contribute to achieving this goal—realising co-benefits for health and environment—but the potential environmental impacts of some proposals need careful evaluation before and during implementation.

Gil Shamai and colleagues1 have produced the most methodologically rigorous computational pathology model to date for recurrence-score estimation in hormone receptor-positive, HER2 (also known as ERBB2)-negative early breast cancer. Leveraging TAILORx randomised treatment assignments to show differential chemotherapy benefit by menopausal status—a distinction no previous computational pathology study has achieved—the model raises the bar for the field. The minimal calibration approach, requiring only 100 slides and no local genomic labels, addresses barriers to deployment in resource-limited settings.

We thank Koinis and colleagues for raising a concern worth clarifying, as other readers might share it. They describe the intermediate-risk population as the group in which stratification is most needed, and argue that our model adds little value there. This conflates two distinct concepts: intermediate clinical or genomic risk and intermediate artificial intelligence (AI) risk. Our AI model is, itself, a stratification tool that resolves subpopulations within the conventionally uncertain clinical and genomic groups, precisely where it is most needed.

Bastiaan M Privé and colleagues reported on the phase 2 trial BULLSEYE, which investigated prostate-specific membrane antigen (PSMA) radioligand therapy with [177Lu]Lu-prostate-specific membrane antigen-617 ([177Lu]Lu-PSMA-617) in patients with PSMA-expressing oligometastatic (≤5 metastases) hormone-sensitive prostate cancer (HSPC), in a setting of biochemically recurrent prostate cancer with a fast prostate-specific antigen (PSA) doubling time of less than 6 months.1 Patients were randomly assigned to 177Lu-PSMA-617 every 6 weeks for up to four cycles or to deferred androgen deprivation therapy (ADT) with active monitoring.

We thank Elif Hindié and colleagues for their thoughtful comments on our recent Article.1 Interest in higher linear energy transfer (LET) radiopharmaceuticals, such as terbium-161 (161Tb), has recently increased.2 161Tb resembles lutetium-177 (177Lu) in its decay but additionally emits low-energy conversion electrons and Auger electrons with high LET. These electrons could induce greater genotoxicity at the cellular level,3 raising the hypothesis that micrometastases could be more effectively treated, similar to proposed advantages of alpha-emitters.

We write as clinicians and cancer survivors who underwent prolonged chemotherapy for oesophageal cancer. Our experiences highlight how access to implantable venous access devices (chemotherapy ports) can shape treatment quality, adherence, and dignity. Although standard in high-income settings, these devices remain unavailable or unaffordable in low-income and middle-income countries (LMICs), revealing an overlooked inequity in cancer care infrastructure.

Al-Thani MBH, Subramanian M, Halabi N, et al. Qatar national cancer care and research: pioneering strategies for global health excellence. Lancet Oncol 2025; 26: e369–80—In this Series paper, the labels for figure 2A have been corrected so that Qatar is the red line and the USA is the blue line. These corrections have been made to the online version as of June 29, 2026.

Over the past 10 years, Philip Morris International (PMI; headquartered at Stamford, CT, USA), a tobacco company, has repeatedly stated its intention to deliver a smoke-free future. According to the PMI website, it is “actively accelerating the decline of cigarette smoking beyond what traditional tobacco control measures can achieve alone.” Nonetheless, a new international advertising drive featuring PMI's flagship brand Marlboro has prompted critics to question the company's commitment to ending sales of combustible cigarettes.

The Public Health Commission in Spain has approved the expansion of the national breast cancer screening programme to include women aged 45–74 years.

On May 26, 2026, the European Cancer Organisation published the European Cancer Screening Policy Index 2026; on May 27, 2026, the American Cancer Society updated its colorectal cancer screening guidance to include blood-based testing for some adults; and Indonesia added colorectal cancer screening to its National Free Health Checkup programme for people aged 45 years and older who are at high risk. These developments come as health systems are under pressure not only to detect cancer earlier, but to ensure that screening is organised, equitable, and followed by diagnosis and care.

To a standing ovation in the Plenary Session, Brian Wolpin (Dana-Farber Cancer Institute, Boston, MA, USA) on behalf of an international team of researchers presented remarkable data from the RASolute 302 phase 3 trial, which showed a doubling of overall survival for patients with metastatic pancreatic adenocarcinoma. Pancreatic cancer is notoriously difficult to treat, but oncogenic RAS mutations are typically seen in more than 90% of cases, offering a unique opportunity for therapy. Daraxonrasib is a new oral, RAS(ON) multiselective, tri-complex inhibitor of mutant and wild type RAS.

The French National Assembly, or the lower house of Parliament, has adopted a private member's bill on a first reading to scale down the amount of cancer-causing cadmium used in phosphate fertilisers in France, from 90 mg/kg to 20 mg/kg by 2030.

The UK Government has pledged £20 million to help improve prostate cancer research and treatment, including the expansion of a landmark screening trial to include all Black men who are eligible.

Campaigners say the USA will reach a “monumental” juncture in September, 2026, when a total of 14 jurisdictions will legally allow medical aid in dying (MAID) after laws in the states of New York and Illinois come into force.

The price of platinum-based cancer drugs in India has been raised in response to a nationwide shortage, following Government approval last week.

*Sachin R Jhawar, Jose G BazanDepartment of Radiation Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43212, USA (SRJ); Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, USA (JGB)

Over 2 billion people currently reside in conflict-affected areas. For millions of people affected by cancer in these areas, disruptions in health services lead to treatment delays or interruptions and, ultimately, amenable deaths. That people should endure both conflict and avoidable cancer death is a double injustice our professional oaths oblige us to confront. The OncoCorridor initiative, led by OncoDaily and the Institute of Cancer and Crisis, aims to reduce avoidable deaths from people diagnosed with cancer in conflict-affected regions by establishing a global network that connects them with treatment centres worldwide.

Aumolertinib in combination with chemotherapy significantly improved progression-free survival. Although this regimen was associated with increased toxicity, the side-effects were managed with dose adjustment and supportive treatment aligned with clinical practice. Long-term follow-up is required to assess overall survival. The AENEAS2 study provides evidence to guide clinical practice regarding EGFR-TKIs and their combination use in treating patients with advanced EGFR-mutated NSCLC.

These data demonstrate that targeting HRD yields promising outcomes in stage III, HER2-negative, HRD breast cancer and that intensified chemotherapy with autologous stem cell rescue does not provide any advantage over state-of-the-art chemotherapy plus olaparib.

Tailoring locoregional radiotherapy in cT1–2N1 breast cancer (with ≤3 nodes at imaging) to the nodal response after primary systemic therapy resulted in a low 10-year locoregional recurrence rate, with promising recurrence-free interval and overall survival. By (partially) omitting radiotherapy based on nodal response after primary systemic treatment, possible morbidity caused by the radiotherapy can be avoided, which could improve patients’ quality of life.

Breast cancer mortality at 20 years was significantly lower in the IM-MS irradiation group, whereas non-breast cancer mortality was numerically higher in the IM-MS irradiation group after 15 years, resulting in no long-term benefit of IM-MS irradiation on overall survival. Our results emphasise the importance of very long-term follow-up and advanced irradiation techniques to reduce the dose to organs of interest.

The ARTO trial showed significant benefit in overall survival with the addition of MDT to systemic therapy versus systemic therapy alone.

[68Ga]Ga-PSMA-11 PET-CT could have the potential to improve the diagnostic pathway of patients with a high clinical risk but non-suspicious or equivocal prostate MRI. Further research, including health-economic analyses and validation with other PSMA radiopharmaceuticals, are needed to confirm the clinical implementation and generalisability of this approach.

Perioperative systemic therapy cannot be recommended in all patients with resectable colorectal peritoneal-only metastases.

Instant, spatially precise dose escalation with intraoperative radiotherapy added to standard of care did not improve outcomes, questioning the value of further local dose intensification in resectable glioblastoma.

ARTIMES-based progression-free survival improves prognostic stratification and shows better trial-level surrogacy for overall survival compared with mRECIST-based progression-free survival. Pending prospective validation, ARTIMES could potentially facilitate a more reliable response evaluation in pleural mesothelioma.

The toxicity profile of T cell-engaging bispecific antibodies varies substantially across cancer types and antibody classes. This meta-analysis provides a comprehensive overview of treatment-related adverse event incidence and patterns, offering a valuable reference for optimising patient management in clinical practice.

Triple-negative breast cancer—the most aggressive breast cancer subtype—has a high propensity for brain metastases, with limited treatments and poor prognosis. The blood–brain barrier, long viewed as an impermeable therapeutic sanctuary, is the core barrier to effective care. This Review advocates a key paradigm shift for clinical and translational research: from merely circumventing the blood–brain barrier to actively targeting and exploiting its biology. We delineate triple-negative breast cancer-specific mechanisms of blood–brain barrier breach and evaluate emerging therapies via a clinically actionable three-pillar framework: physical and focal blood–brain barrier disruption, biological blood–brain barrier exploitation, and microenvironmental modulation.

Imaging is central to diagnosing, staging, evaluating treatment response, and guiding post-therapy surveillance in osteosarcoma and Ewing sarcoma, yet no international consensus defines optimal modalities or schedules. This European guideline, developed by 36 multidisciplinary experts, seeks to standardise imaging for research and enhance patient care. A systematic review identified 2026 studies, of which 13 met criteria, revealing marked heterogeneity in diagnoses, chemotherapy regimens, and imaging protocols.

Reirradiation can be considered for some patients with recurrent or second primary head and neck squamous cell carcinoma arising within previously irradiated regions, a clinical scenario associated with few therapeutic options. The increasing use of modern conformal radiotherapy techniques, including intensity-modulated radiotherapy, proton therapy, and stereotactic body radiotherapy, has expanded the feasibility of reirradiation in clinical practice. However, evidence remains heterogeneous, and clinical choices are challenged by substantial variability in patient presentation, previous treatments, and toxicity risk.

This study identifies a proliferative ecotype of UC that is orthogonal to classical luminal/basal ecotypes. Despite its adverse prognosis, this ecotype confers superior responsiveness to chemotherapy and immunotherapy and features a distinct genomic and immune ecosystem. These findings position proliferative status as a clinically actionable axis that may refine molecular classification and guide precision therapy in UC.

Pediatric cancer survival has continued to improve. However, differences persist by age, sex, race and ethnicity, economic status, geography, and cancer type.

Postoperative anlotinib plus radiotherapy demonstrated clinically meaningful activity with a manageable safety profile in patients with unmethylated MGMT glioblastoma (Chinese Clinical Trials Registry identifier: ChiCTR2000040116).

In patients with very high‐risk NMIBC, magnetic resonance imaging–derived radiomic phenotypes can be used to stratify responses to immunochemotherapy and capture functional immune states. Noninvasive radiomic profiling may guide precision treatment selection in patients who are unfit for radical cystectomy, and prospective validation is warranted before clinical adoption.

TB + iSB met the prespecified noninferiority criterion for csPCa detection relative to TB + SB and may represent a promising core‐reduction strategy in transperineal MRI‐guided biopsy, although the full protocol still provided additional contralateral information.

The addition of olaparib to radium‐223 was not associated with significant detriment to PROs or pain, which supports the tolerability of this combination.

Selinexor combined with azacitidine or ruxolitinib showed encouraging efficacy with a manageable safety profile in patients with MDS/MPN.

This analysis of 2 cohort studies and a mouse model examined the association of clonal hematopoiesis of indeterminate potential with cardiotoxic effects in patients with breast cancer receiving trastuzumab.

This systematic review and meta-analysis assesses the prognostic value of pretreatment magnetic resonance imaging (MRI) parameters for oncological outcomes in men undergoing radical prostatectomy.

This cohort study examines characteristics and context of adolescent and young adult patients with cancer who use medical assistance in dying in Alberta, Canada.

This randomized clinical trial evaluates the efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy vs placebo plus pembrolizumab plus chemotherapy in patients with advanced nonsquamous non–small cell lung cancer.

This population-based cross-sectional analysis quantifies adult T-cell leukemia/lymphoma incidence by race, ethnicity, and detailed country of birth in the US.

This systematic review and meta-analysis examines outcomes of local therapy without systemic therapy for radiorecurrent prostate cancer.

This cohort study examines subsequent treatments and outcomes for patients with non–small cell lung cancer after pembrolizumab discontinuation following 2 years of therapy.

This cohort study compares the AQUILA trial inclusion criteria and the 2/20/20 risk stratification model definitions for identifying individuals with smoldering multiple myeloma at high risk of progression.

This genomic profiling study describes the molecular architecture of 1104 prospective consecutive meningioma samples from one academic medical center.

This cross-sectional study examines trends in colorectal cancer mortality rates among individuals aged 25 to 49 years by educational attainment, as a marker of socioeconomic status.

This cohort study examines the associations of minimally invasive surgery, intraoperative capsule rupture, and overall survival among patients with stage I ovarian cancer.

This secondary analysis of a nonrandomized clinical trial assesses long-term survival and genomic variants associated with therapeutic resistance in patients receiving maintenance rucaparib with

This cross-sectional study uses data from the 2011-2020 US National Health and Nutrition Examination Survey to evaluate trends and patterns in receipt of lifestyle advice and ongoing lifestyle practices for weight control, physical activity, and dietary intake among cancer survivors.

A 60-year-old woman presented with progressive right lower extremity radiculopathy and numbness, a pigmented skin lesion on the right side of the chest, and right ankle jerk reflex. Magnetic resonance imaging of the lumbar spine revealed multiple intradural, contrast-enhancing lesions. What is your diagnosis?

This Viewpoint describes how parents of young adults with cancer navigate myriad psychosocial challenges related to their child’s specific life stage, and how these necessitate specialized support that may currently be overlooked in young adult cancer care.

This Viewpoint examines the underutilization of glucagon-like peptide-1 receptor agonists and bariatric surgery in survivors of cancer.

This Viewpoint discusses food insecurity among individuals with cancer and proposes strategies to address this issue, including routine screening, advocating for policy reform, and connecting patients with community resources.

This Viewpoint discusses the curative/palliative dichotomy used to describe the framework of cancer care and how it may affect care trajectories, patient-centered communication, shared decision-making, and advance care planning.

This essay describes the author’s grieving process with the death of their father.

June 19, marks World Sickle Cell Day, with the 2026 theme focusing on closing the survival gap and a push towards a universal cure. 20 years have passed since the WHO recognised sickle cell disease as a global health problem, and although some progress has been made, there is clearly still substantial work to be done to improve outcomes for those living with the disease around the world.

The diagnosis of primary CNS lymphoma has traditionally relied on stereotactic brain biopsy, while cytological analysis of cerebrospinal fluid (CSF) or vitreous humour is diagnostic in only a minority of patients.1 Although essential for histopathological confirmation, brain biopsy carries inherent risks, with mortality rates ranging from 0·8% to 2·2%, and might cause substantial delays in treatment initiation.1 Consequently, the development of reliable, less invasive diagnostic approaches has become a major objective in the management of primary CNS lymphoma.

Bone marrow examination is integral to the diagnosis and classification of myeloproliferative neoplasms, but is invasive, can be technically challenging, and is not always immediately feasible. Marie Donzel and colleagues present the Fibrosis Prediction in Bone Marrow using Artificial Intelligence (FIBOM-AI) model,1 a machine learning model trained to predict grade 2–3 bone marrow fibrosis using only age and routine complete blood count (CBC) parameters. Developed from a multicentre cohort using data from 1995 patients with a suspected or established myeloproliferative neoplasm across 13 French centres, and evaluated with both external and prospective validation, this study offers a practical example of how artificial intelligence (AI) can extract insights from routine, inexpensive laboratory data.

Sickle cell disease is one of the most common severe hereditary disorders worldwide. More than 500 000 infants are born with sickle cell disease each year, the majority in sub-Saharan Africa, where early diagnosis and comprehensive care remain limited.1 Advances in neonatal screening and infection prevention have improved survival, but this success has also exposed the growing lifetime burden of cerebrovascular disease.1 Stroke is a leading cause of morbidity, cognitive impairment, and disability in sickle cell disease.

We write as an international group of qualitative researchers working within haematology. We commend Prasanna Ananth and colleagues for their expert recommendations on conducting and appraising qualitative research, including five pillars that support best practice in qualitative studies.1 Quantitative research can tell us what and how much, but qualitative and mixed methods studies help explain why. These approaches are essential for creating and evaluating interventions that work in real-world contexts.

“Where is Talal?” one of the fellows asked.“Probably in the library” another replied with a chuckle.

Chronic lymphocytic leukaemia is often described as indolent—a leukaemia that unfolds slowly, sometimes over decades. In older adults, it behaves less like an acute malignancy and more like a chronic companion. Many patients are diagnosed incidentally and require no immediate therapy. The biology might be calm but the lived experience rarely is.

When Ayako Arai was at medical school in the late 1980s, she became fascinated with the “extraordinary beauty” of blood cells under a microscope. At the time, haematopoietic stem-cell transplantation (HSCT) was just becoming established and the concept of molecular targeted therapy beginning to emerge.

“You Look Fine” begins with LA-based comedian Jared “J” Snow trying a bit of boxing. His trainer holds the mitts and calls the combinations. Jab, right, hook, right, roll, finish with another right. J lands punches, moves competently around the ring, and rests when the bell sounds. After three rounds, he starts feeling discomfort in his chest, so he stops training and goes home to bathe in Epsom salts and swallow some painkillers. He hopes this will be enough to forestall a sickle cell crisis.

Adverse events were few, probably due to organ sparing by total marrow and lymphoid irradiation. Total marrow and lymphoid irradiation 2000 cGy could be safely delivered in combination with high-dose etoposide and cyclophosphamide. The regimen was associated with encouraging 2-year progression-free survival rates.

In this prospective, multicentre cohort of patients with suspected primary CNS lymphoma, we validated the high diagnostic value of MYD88, IL-10, and CXCL13. Results should be interpreted within the full clinical context and with caution, as the diagnostic algorithm and decision tree were derived within the same cohort. In selected clinical scenarios and with further validation of these results, combined CSF biomarker testing might support non-invasive diagnostic decision making and reduce reliance on brain biopsy.

This study showed a high prevalence of post pulmonary embolism syndrome in children with pulmonary embolism. Different clinical factors can contribute, including psychological distress factors and physical limitations, emphasising the need for comprehensive, multidisciplinary care.

FIBOM-AI can be reliably used as a triage and prioritisation tool to support timely bone marrow evaluation or provide complementary risk assessment when bone marrow biopsy is not immediately feasible.

Donor cell-derived haematological neoplasms (DDHN) are rare disorders and currently do not have standardised diagnostic criteria and therapeutic management. International experts in allogeneic transplantation and haematological malignancies from Europe, the Americas, and Australia worked together on behalf of the EBMT Practice Harmonisation and Guidelines Committee to delineate a pragmatic diagnostic framework and issue guidance for downstream clinical management for DDHN. The team met on Sept 18–19, 2025, in Berlin, Germany, to discuss the definition, molecular insights, treatments, and donor outcomes for DDHN after an intensive review of the literature.

Sickle cell disease is a haematological disorder marked by recurrent events and progressive organ dysfunction, yet a standardised framework to assess disease severity is lacking. We developed a novel US-based severity grading system through identification of sickle cell disease-related complications mapping all to the Common Terminology Criteria For Adverse Events and applying a five-level severity scale. A modified Delphi process involving 29 US-based sickle cell disease experts was conducted over three virtual rounds (from Oct 20 to Nov 8, 2023; from June 26 to Aug 1, 2024; and from Nov 6, 2024, to Jan 7, 2025), with the use of a 9-point Likert scale ratings and iterative feedback.

An 83-year-old woman presented to our haematology department in June, 2025, with a 3-month history of palpable cervical lymphadenopathy and splenomegaly. Contrast-enhanced CT revealed enlarged cervical, axillary, inguinal, and visceral lymphadenopathy. A biopsy of a cervical lymph node verified a diagnosis of stage IV angioimmunoblastic T-cell lymphoma (AITL; appendix pp 3–4). Immunohistochemistry showed atypical T cells positive for CD3, CD4, CD10, CD30, ICOS, BCL6, and PD1. In-situ hybridisation for Epstein–Barr virus (EBV)-encoded RNA (EBER) testing was negative (appendix p 7).

Understanding of the pathophysiology of cold agglutinin disease (CAD) has serially led to the use of B-cell–targeted therapies such as rituximab-based regimens and, more recently, complement pathway inhibitors. CAD arises through formation of immunoglobulin M autoantibodies, which bind the I antigen on red cells, triggering agglutination and also complement activation resulting in extravascular hemolysis. Under stress conditions, complement activation is amplified and intravascular hemolysis becomes a dominant clinical feature. In this Perspective, Fattizzo, Miyakawa, and Broome summarize key data and provide their expert opinion as to when to use rituximab, rituximab-based chemoimmunotherapy, or sutimlimab and other complement pathway inhibitors.

Bussel, Hirshman, and Kapur review the diagnosis, pathophysiology, and management of anti–human platelet antigen 1a (HPA-1a)–mediated fetal-neonatal alloimmune thrombocytopenia as understood in 2026. By integrating data on evolving diagnostic strategies, their synthesis encourages the field to reconsider current approaches and may help improve outcomes for affected pregnancies and newborns.

The use of haploidentical donors for allogeneic hematopoietic stem cell transplantation has greatly expanded its application, enabled by advances in graft-versus-host disease (GVHD) prevention, primarily the use of antithymocyte globulin (ATG) or posttransplant cyclophosphamide (PTCy). Yang and colleagues report the first randomized phase 3 trial to directly compare PTCy, ATG, and their low-dose combination for preventing GVHD after haploidentical peripheral blood stem cell (PBSC) transplantation for acute myeloid malignancies, finding no significant differences in any GVHD or survival end points across the 3 strategies. While several questions remain unresolved, these important data validate the use of either agent or the low-dose combination in practice.

High CD49d expression identifies patients with more aggressive chronic lymphocytic leukemia (CLL) and poor survival, but the functional basis for this is speculative. Polcik and colleagues confirm that CD49d is necessary for CLL cell homing to the bone marrow and for localization in the secondary lymphoid organs and that its expression levels are associated with distinct bone marrow infiltration patterns in patients. They also reveal its importance in controlling B-cell receptor (BCR) responsiveness by organizing the actin cytoskeleton and regulating immune synapse formation, thereby suggesting that it could be a therapeutic target worthy of future investigation.

In multiple myeloma (MM), transcriptional regulators such as MYC, interferon regulatory factor 4 (IRF4), and MAF are important. In a search for potential therapeutic targets, Gómez-Echarte et al integrated functional genomics, mechanistic studies, and clinical data to identify IRF2 as an essential transcription factor in MM. IRF2 links oncogenic transcription to repression of necroptosis and disease dissemination and is an independent prognostic biomarker that adds discriminatory power to current standard algorithms for prognostication.

It is now appreciated that most cases of acute myeloid leukemia (AML) have clonal heterogeneity, and, as a result, the relationships between genotype, immunophenotype, and treatment outcome can be confusing. Drucker et al used single-cell analyses of 43 samples from patients with NPM1-mutated AML to reveal that comutations in epigenetic regulators shape immunophenotype while mutations in signaling pathways increase clonal complexity. Such insights reinforce the need for physicians to adapt treatment paradigms to accommodate the limitations in prediction afforded by standard genotyping.

Iron is essential, but at high levels it can be toxic, with each cell type having distinct requirements and mechanisms for utilizing the metal. Using murine models of iron overload, Sighinolfi et al report that iron damages mitochondria in hematopoietic stem cells (HSCs), leading to fewer active mitochondria, oxidative stress, and upregulated glycolysis. Restoring mitochondrial function by targeting reactive oxygen species improved the quiescence and self-renewal of HSCs in a mouse model of β-thalassemia. These findings further encourage efforts to reduce iron loading in thalassemias, myelodysplasias, and transfusional iron overload states.

Traumatic brain injury (TBI) disrupts the blood brain barrier (BBB) and injures the microvasculature, causing bleeding, hyperfibrinolysis, and sometimes consumptive coagulopathy, yet the evidence for empiric use of platelet infusions is not supported by evidence in the absence of severe thrombocytopenia. Trivedi and colleagues studied a murine model of traumatic brain injury, showing that freeze-dried platelets preserve the BBB, dampen neuroinflammation, improve cerebral blood perfusion, and reduce intracerebral hemorrhage. These provocative results warrant early phase clinical trials with selected patients with serious brain trauma.

New England Journal of Medicine, Volume 394, Issue 24, Page 2429-2439, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2395-2406, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2419-2428, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2407-2418, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2487-2488, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2481-2483, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2477-2479, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2474-2476, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2473-2474, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2459-2459, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2390-2392, June 25, 2026.

New England Journal of Medicine, Volume 394, Issue 24, Page 2385-2387, June 25, 2026.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

New England Journal of Medicine, Ahead of Print.

The American Association for Cancer Research (AACR) released its Cancer Disparities Progress Report 2026 on June 24. The report features the unprecedented progress being made against cancer, including the ongoing decline in cancer death rates, which have decreased by 35% since 1991, translating to...

A new Columbia University School of Nursing systematic review published by Algave et al in the journal Cancer reveals access to fertility preservation care remains limited and unequal for girls and young women with cancer.

In a meta-analysis reported in The Lancet Oncology, Zhu et al identified treatment-related adverse events associated with the use of CD3-based T-cell–engaging bispecific antibodies in patients with hematologic or solid cancers.

Most patients who receive a cancer diagnosis still prefer to learn of the diagnosis from their doctors rather than from reports uploaded to their online health portal, according to findings of a survey conducted at the University of Texas Southwestern Medical Center. Findings were published as a...

Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), improving surgical bed control and overall survival while maintaining a comparable safety profile,...

Existing agents such as statins and beta-blockers showed cardioprotective properties in select subgroups, but more treatments are needed to protect against heart failure in patients receiving treatment for cancer, according to findings from a systematic review and meta-analysis presented at the...

In a French phase I/II trial (TROPHAMET) reported in JAMA Oncology, You et al found that first-line avelumab plus methotrexate was associated with high efficacy in patients with low-risk gestational trophoblastic tumors.

In an analysis reported in the Journal of Clinical Oncology, Wilson et al found that prophylactic high-dose methotrexate does not provide significant benefit in reducing central nervous system (CNS) relapse in patients with ultra–high-risk large B-cell lymphoma (LBCL).

On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved the antibody-drug conjugate sacituzumab govitecan-hziy (Trodelvy) for two indications in adults with triple-negative breast cancer (TNBC).

Using artificial intelligence (AI), researchers found that image-based risk scores for breast cancer derived from screening mammograms evolve over time and differ between women who develop cancer and those who do not, opening the door to a new era of dynamic breast cancer risk assessment. The new...

A large real-world study conducted across six Asian countries suggests that a blood-based multi-cancer early detection (MCED) test may accurately identify multiple cancer types in routine clinical practice, including cancers for which no standard screening programs currently exist. The research was ...

Treatment with the PI3K inhibitor inavolisib in combination with palbociclib and fulvestrant produced substantial clinical benefits in Asian patients with PIK3CA-mutated, hormone receptor–positive (HR-positive), HER2-negative, endocrine-resistant advanced breast cancer, according to a subgroup...

A large retrospective cohort study found that GLP-1 receptor agonist use was associated with significantly lower 5-year rates of colorectal cancer among patients with inflammatory bowel disease (IBD). The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting,...

A HER2-targeted regimen produced high pathologic complete response rates before surgery in patients with locally advanced HER2-positive breast cancer, according to results from a single-arm phase II neoadjuvant trial conducted in China. The research was highlighted in a media briefing ahead of the...

Early integration of palliative, or supportive, care at the time of breast cancer diagnosis improved quality of life more than on-demand palliative care in a randomized trial of patients in India. The research was highlighted in a media briefing ahead of the 2026 ASCO Breakthrough Meeting, taking...

On June 24, 2026, the U.S. Food and Drug Administration (FDA) approved palbociclib (Ibrance) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adult patients with hormone receptor (HR)-positive, HER2-positive locally advanced or...

In an interim analysis of a Chinese phase III trial (FCN-437c-III201) reported in JAMA Oncology, Yuan et al found that the addition of the novel CDK4/6 inhibitor fovinaciclib to aromatase inhibitor therapy was associated with significant improvement in progression-free survival in the first-line...

Educational gaps in cardio-oncology training have been identified in the results of an international survey presented at the European Society of Cardiology (ESC) Congress 2026.

In an interim analysis of a phase III trial (MonumenTAL-3) reported in The New England Journal of Medicine, Mina et al found that the combinations of talquetamab with daratumumab/pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) improved progression-free survival vs...

Researchers have found that wearable devices may help clinicians detect cytokine-release syndrome—a common and potentially serious side effect of chimeric antigen receptor (CAR) T-cell therapy—hours earlier than standard hospital monitoring in patients with multiple myeloma.  

In a Chinese phase III trial (AENEAS2) reported in The Lancet Oncology, Li et al found that the combination of aumolertinib with chemotherapy significantly improved progression-free survival vs aumolertinib alone in patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC).

In a long-term individual patient-level pooled analysis reported in the Journal of Clinical Oncology, Gandini et al found that low-dose tamoxifen was associated with good outcomes in patients with noninvasive breast neoplasia.

Researchers have developed and validated an artificial intelligence (AI)‒assisted volumetric response criteria for assessing response in pleural mesothelioma. The AI-backed criteria outperformed both humans and standard international Response Evaluation Criteria in Solid Tumors (RECIST) criteria,...

In a Chinese phase I dose-escalation and dose-expansion study reported in the Journal of Clinical Oncology, Qi et al found that guanylyl cyclase 2C (GUCY2C)-targeted chimeric antigen receptor (CAR) T-cell therapy had an “acceptable” safety profile and was active in patients with previously treated...

Right ventricle (RV) dysfunction is associated with poorer outcomes in heart failure with preserved ejection fraction (HFpEF). Females are more likely to have HFpEF but males have worse prognosis and resting RV function. The contribution of dynamic RV-pulmonary artery (RV-PA) coupling between sex and its impact on peak exercise capacity (VO2) in HFpEF is not known.

A Phase I, single-center investigation demonstrated that 8 weeks of antimycobacterial therapy improved sarcoidosis forced vital capacity (FVC). Safety and efficacy assessments have not been performed in a multicenter cohort.

All aspects of medical education were affected by the Novel Coronavirus Infectious Disease-19 (COVID-19) pandemic. Several challenges were experienced by trainees and programs alike due to the economic repercussions of the pandemic, how social distancing affected the delivery of medical education, testing and interviewing, how the surge of patients affected redeployment of personnel, potential compromise in core training and the overall impact on the wellness and mental health of trainees and educators.

In this meta-analysis of observational studies, RV dysfunction was associated with higher short-term and long-term mortality in sepsis and septic shock.

Legionella is an uncommon cause of CAP, occurring primarily from late spring through early autumn. Testing is uncommon, even among patients with risk factors, and many positive patients failed to receive empiric coverage for LP.

The nS classification could be used to provide a more accurate prognosis in patients with resected NSCLC. The nS is worth taking into consideration when defining nodal category in the forthcoming ninth edition of the staging system.

NLP successfully identified a large cohort with CC. Most patients were identified through NLP alone, rather than diagnoses or medications. NLP improved detection of patients nearly seven-fold, addressing the gap in ability to identify and characterize CC disease burden. Nearly all cases appeared to be managed in primary care. Identifying these patients is important for characterizing treatment and unmet needs.

Pulmonary arterial hypertension (PAH) is a rare disease and much of our understanding stems from single-center studies, which are limited by sample size and generalizability. Administrative data offer an appealing opportunity to inform clinical, research, and quality improvement efforts for PAH. Yet, there is currently no standardized, validated method to distinguish PAH from other subgroups of pulmonary hypertension (PH) within this data source.

A transparent DL algorithm improves on traditional clinical criteria to predict the need for MV in hospitalized patients, including in those with COVID-19. Such an algorithm may help clinicians optimize timing of tracheal intubation, better allocate resources and staff, and improve patient care.

To assess airway and lung parenchymal damage non-invasively in cystic fibrosis (CF), chest MRI has been historically out of the scope of routine clinical imaging due to technical difficulties such as the low proton density and respiratory and cardiac motion. However, technological breakthroughs have recently emerged to dramatically improve lung MRI quality (including signal-to-noise ratio, resolution, speed, contrast). At the same time, novel treatments have changed the landscape of CF clinical care.

Bronchoscopic lung volume reduction with one-way endobronchial valves is a guideline treatment option for patients with advanced emphysema, supported by extensive scientific data. Patients limited by severe hyperinflation, with a suitable emphysema treatment target lobe and with absence of collateral ventilation are the responders to this treatment. Detailed patient selection, a professional treatment performance, and dedicated follow-up of the valve treatment, including management of complications, are key ingredients to success.

Chronic Obstructive Pulmonary Disease (COPD) may cause profound dyspnea, functional impairment, and reduced quality of life. Available pharmacologic therapy provides suboptimal symptom improvement in many patients. Bronchoscopic lung volume reduction (BLVR), achieved with endobronchial valve (EBV) placement, can effectively improve dyspnea and functional status in appropriately selected patients. Operationalizing a safe and effective BLVR program requires appropriate oversight which can be achieved by a BLVR Nurse Coordinator (NC).

Empathy-based, stigma-reducing communication may lead to improved assessments of tobacco use and smoking cessation for patients with smoking-related cancers. These findings support the dissemination and further testing of a new ECS model for training OCPs in best practices for assessment of smoking history and engagement of patients who currently smoke in tobacco treatment delivery.

In clinical practice, reslizumab may have been initiated in response to heavy symptom burden and CAEs. Reslizumab was associated with improved clinical and patient-reported outcomes and significant reductions in asthma-related HRU.

Quantitative emphysema measured on LDCT of the chest can be leveraged to improve lung cancer risk prediction and help diagnose COPD in individuals who currently or formerly smoked undergoing lung cancer screening.

Modern oncology has built highly efficient pathways for patent-protected innovation, but no equivalent machinery for evaluating and developing promising off-patent therapeutics. Herein, we frame ‘open-source oncology’ as a parallel public-interest infrastructure to test, authorize and implement credible generic agents. Designed to translate ownerless evidence into standard-of-care treatments, this framework applies the same scientific seriousness devoted to proprietary drugs, decoupling clinical value from commercial ownership.

Over the past decades, cancer epidemiology trends have substantially shifted in China, with a rapid increase in incidence of cancers that are most common in high-income countries and a substantial decline in incidence of cancers historically prevalent in China. The authors of this Review provide an overview of cancer epidemiology in China, a major contributor to global cancer burden, and discuss national cancer control policies and targets.

The therapeutic landscape of platinum-resistant ovarian cancer is rapidly evolving, with recent phase III trials demonstrating, for the first time, meaningful overall survival improvements beyond bevacizumab-based therapy. Herein we discuss how trials such as MIRASOL and, more recently, ENGOT-ov65/KEYNOTE-B96 and GOG30173/ENGOT-ov72/ROSELLA have established new standards of care through distinct biologically driven therapies and outline the new challenges that these approaches expose.

Three antibody–drug conjugates (ADCs) are currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for solid tumours expressing HER2 and tisotumab vedotin for cervical cancer (independent of tissue factor expression). The authors of this Review discuss current priorities in the clinical development of ADCs for gynaecological cancers, such as identifying novel targets, understanding mechanisms of resistance and sequencing strategies, and managing toxicities, highlighting key advances and future opportunities.

Teclistamab monotherapy improves survival in RRMM

Potential new standard of care for resectable gastro-oesophageal adenocarcinoma in Asia

Daraxonrasib effective in metastatic pancreatic ductal adenocarcinoma

Adjuvant selpercatinib shows benefit in patients with NSCLC

Annals of Internal Medicine, Volume 179, Issue 6, Page 765-772, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 773-784, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 785-793, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 794-803, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 804-811, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 812-822, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 823-834, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 842-856, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 857-867, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 835-838, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 839-841, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 868-873, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 874-884, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 885-888, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 889-891, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 892-894, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 895-897, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 898-899, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 900-901, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 902, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 903-904, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 905-906, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 908-911, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 911-914, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 915-916, June 2026. <br/>

Annals of Internal Medicine, Volume 179, Issue 6, Page 914, June 2026. <br/>

A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.

Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.

As uniQure prepares its closely watched Huntington’s disease gene therapy for FDA review, the biotech is also making waves in chronic epilepsy with another gene therapy that Stifel says is off to a “promising start.”

Backed by institutional investors and seasoned industry leaders, cAMPfield Therapeutics is advancing a clinical program aimed at reshaping the landscape for inflammatory bowel disease.

Following the mid-stage readout, Verastem Oncology has decided to move away from its investigational pancreatic cancer drug combo, instead putting resources behind its KRAS inhibitor pill for solid tumors.

While falling short of statistical significance, Incyte and Mirum Pharmaceuticals’ ALK2 inhibitor showed a “clear benefit” in reducing abnormal bone formation in a Phase 2 study of fibrodysplasia ossificans progressiva.

Elicio Therapeutics’ investigational cancer immunotherapy failed to meet the primary endpoint of disease-free survival in a Phase 2 trial—a result the company attributed mostly to a disproportionate number of patients with higher residual disease.

Rhythm Pharmaceuticals’ Imcivree reduced fat—while boosting muscle—in patients with Prader-Willi syndrome.

The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.

BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.

Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.

The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space.

Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.

Despite an overall survival miss, Leerink Partners said Pfizer’s antibody-drug conjugate showed “promising” signals of efficacy in a subgroup of patients who had undergone only one prior line of treatment.

Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to Stifel, while Jefferies called the efficacy data “profound.”

With a one-time dosing profile, Intellia Therapeutics’ gene editing asset could be “paradigm-shifting” for hereditary angioedema, according to Jefferies. The biotech anticipates market approval next year.

Neumora Therapeutics is laying off 35% of workers after its most advanced asset failed a pair of Phase 3 studies, sending the biotech’s stock spiraling early Monday.

Takeda eyes an FDA run for its investigational psoriasis pill after the drug elicited total skin clearance in more than 35% of patients at 16 weeks—more than 2.5 times that in controls taking Bristol Myers Squibb’s Sotyktu.

The discontinuation of Sanofi’s Phase 3 study for its complement inhibitor drug in chronic inflammatory demyelinating polyneuropathy delivers an ‘obviously disappointing’ blow to the broader drug class, according to William Blair.

With the failure in chronic spontaneous urticaria, Evommune’s story is now centered on its anti-IL-18 therapy EVO301, Oppenheimer said, which in February elicited a 33% placebo-adjusted improvement in eczema severity.

A recent FDA reversal sparked new hope for patients with Huntington’s disease. Flying under the radar, Skyhawk Therapeutics revealed 12-month functional data from a midstage trial of its own candidate showing improvements on a key disease measurement scale.

BridgeBio Pharma plans to file for approval in the third quarter. If granted, the oral drug could present a “highly differentiated” option over current achondroplasia therapies, according to Jefferies.

Recent approvals for Corcept Therapeutics and Merck have injected momentum into the space, where GSK, Allarity Therapeutics, OSE Immunotherapies and others are advancing their own candidates.

The positive ADHD data for Otsuka Pharmaceutical’s centanafadine is good news in what has of late been a mixed bag for the neuropsychiatric space.

Policymaking at FDA has been anything but business as usual under the Trump administration, but former regulators cite the agency’s new investigational new drug pilot program as a sign of normalcy.

In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you’ll hear from Hakan Goker, managing director at M Ventures and Maina Bhaman, partner at Sofinnova Partners. We explore the UK biotech ecosystem: from the Golden Triangle’s evolving role to the challenges of scaling companies, unlocking pension capital and staying globally competitive.

Encouraging data for combination regimens of Revolution Medicines’ zoldonrasib “reinforce the path to leadership in PDAC” for the biotech, according to Truist Securities.

Recent BioSpace industry conference conversations point to sponsors pushing earlier on safety, quality and performance data, leading to demand for nitrosamine analysis, IVRT/IVPT and microbiome database capabilities.

Given its intravenous route of administration, Merck’s tulisokibart will likely “need to be meaningfully improved” over Roche’s afimkibart, which can be given subcutaneously, BMO Capital Markets analysts said. Both assets are being tested for ulcerative colitis.

On June 30, 2026, the Food and Drug Administration approved allogeneic regulatory T cell-based immunotherapy with hematopoietic stem and progenitor cell (HSPC) and T cells-vldq (Tregzi, Orca Bio) for use in matched donor hematopoietic stem cell transplantation (HSCT) with a myeloablative preparative regimen, for hematopoietic and immunologic reconstitution and to improve chronic graft-versus-host disease (cGHVD)-free survival, in the treatment of adults with hematological malignancies.

On June 24, 2026, the Food and Drug Administration approved sacituzumab govitecan-hziy (Trodelvy, Gilead Sciences, Inc.) for two indications in adults with triple-negative breast cancer (TNBC). 

On June 24, 2026, the Food and Drug Administration approved palbociclib (Ibrance, Pfizer Inc.) in combination with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of adults with HR-positive, HER2-positive locally advanced or metastatic breast cancer following induction treatment.

On June 12, 2026, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca) in combination with abiraterone and prednisone for adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer) that is PTEN-deficient as detected by an FDA-authorized test.

On June 12, 2026, the Food and Drug Administration approved belzutifan (Welireg, Merck & Co., Inc.) in combination with pembrolizumab (Keytruda, Merck & Co., Inc.) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck & Co., Inc.) for the adjuvant treatment of adults with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.

On May 28, 2026, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) in combination with Bacillus Calmette-Guerin (BCG) for the treatment of adult patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC).

On May 27, 2026, the Food and Drug Administration approved pivekimab sunirine-pvzy (Decnupaz, AbbVie, Inc.), a CD123-directed antibody and alkylating agent conjugate, for adults with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

On May 22, 2026, the Food and Drug Administration approved datopotamab deruxtecan-dlnk (Datroway, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.

On May 15, 2026, the Food and Drug Administration (FDA) approved fam-trastuzumab deruxtecan-nxki (T-DXd, Enhertu, Daiichi Sankyo, Inc.) for two separate indications in adults with HER2-positive early-stage breast cancer. The first indication is for T-DXd followed by a taxane, trastuzumab, and pertuzumab (THP), for the neoadjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) Stage II or III breast cancer, as determined by an FDA-authorized test. The second indication is for T-DXd for the adjuvant treatment of adult patients with HER2-positive (IHC 3+ or ISH+) breast cancer who have residual invasive disease following neoadjuvant treatment with trastuzumab (with or without pertuzumab) and taxane-based treatment.

On May 15, 2026, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc. and atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) as adjuvant treatments for adults with muscle invasive bladder cancer (MIBC) after cystectomy who have circulating tumor DNA molecular residual disease (ctDNA MRD) as determined by an FDA-authorized test.

On May 13, 2026, the Food and Drug Administration approved an oral combination of decitabine and cedazuridine tablets (Inqovi, Taiho Oncology, Inc.) with venetoclax for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy.

On May 13, 2026, the Food and Drug Administration granted accelerated approval to sonrotoclax (Beqalzi, BeOne Medicines USA, Inc.), a BCL-2 inhibitor, for adults with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a Bruton’s tyrosine kinase (BTK) inhibitor.

On May 8, 2026, the Food and Drug Administration approved zenocutuzumab-zbco (Bizengri, Partner Therapeutics, Inc.) for adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy. NRG1-fusion positive cholangiocarcinoma is an extremely rare, life-threatening malignancy.

On May 1, 2026, the Food and Drug Administration approved vepdegestrant (Veppanu, Arvinas Operations, Inc.), a heterobifunctional protein degrader, for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy. 

On March 25, 2026, the Food and Drug Administration approved relacorilant (Lifyorli, Corcept Therapeutics Inc.), a glucocorticoid receptor antagonist, in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.

On March 20, 2026, the Food and Drug Administration approved nivolumab (Opdivo, Bristol Myers Squibb Company) with doxorubicin, vinblastine, and dacarbazine (AVD) for adult and pediatric patients 12 years and older with previously untreated, Stage III or IV classical Hodgkin lymphoma (cHL).

On March 5, 2026, the Food and Drug Administration approved teclistamab (Tecvayli, Janssen Biotech, Inc.) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent. 

On February 26, 2026, the Food and Drug Administration granted accelerated approval to zongertinib (Hernexeos, Boehringer Ingelheim Pharmaceuticals, Inc.), a kinase inhibitor, for an expanded indication for adults with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.

On February 24, 2026, the Food and Drug Administration granted traditional approval to encorafenib (Braftovi, Array BioPharma Inc., a subsidiary of Pfizer Inc.) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-authorized test. Encorafenib received accelerated approval in combination with cetuximab and mFOLFOX6 for metastatic colorectal cancer with BRAF V600E mutation in 2024. 

On February 19, 2026, the Food and Drug Administration approved acalabrutinib (Calquence, AstraZeneca) tablets and capsules in combination with venetoclax (Venclexta, AbbVie Inc. and Genentech Inc.) for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

On February 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) as well as pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) in combination with paclitaxel, with or without bevacizumab, for adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 (CPS≥1) as determined by an FDA-authorized test, and who have received one or two prior systemic treatment regimens.

On January 27, 2026, the Food and Drug Administration approved daratumumab and hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant (ASCT).

On December 17, 2025, the Food and Drug Administration approved amivantamab and hyaluronidase-lpuj (Rybrevant Faspro, Janssen Biotech, Inc.) for subcutaneous injection for adult patients across all indications approved for the intravenous formulation of amivantamab (Rybrevant, Janssen Biotech, Inc.). See the prescribing information for the specific indications.

Pan Afr Med J. 2026 Mar 26;53:144. doi: 10.11604/pamj.2026.53.144.51276. eCollection 2026.
Sadaoui I, Sadaoui I, Joutei HAH, Benomar H, Nadifi S

Med Mycol J. 2016;57(2):E21-5. doi: 10.3314/mmj.57.E21.
Noguchi H, Hiruma M, Miyashita A, Makino K, Miyata K, Ihn H

Cureus. 2018 Aug 29;10(8):e3231. doi: 10.7759/cureus.3231.
Pantiora EV, Sakellaridis EP, Kontis EA, Fragulidis GP

Nucleic Acids Res. 2000 Sep 15;28(18):3411-6. doi: 10.1093/nar/28.18.3411.
Trzcinska-Danielewicz J, Fronk J

J Am Acad Child Adolesc Psychiatry. 1996 Dec;35(12):1602-10. doi: 10.1097/00004583-199612000-00011.
Brown RA, Lewinsohn PM, Seeley JR, Wagner EF

AoB Plants. 2014 Jun 9;6:plu030. doi: 10.1093/aobpla/plu030.
Begley-Miller DR, Hipp AL, Brown BH, Hahn M, Rooney TP

Circulation. 2026 Jun 29. doi: 10.1161/CIR.0000000000001455.
Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, Bozkurt B, Cikes M, Damasceno A, Desai AS, Felker GM, Hogan G, Kinugawa K, Kittleson M, Lam CSP, McDonagh T, Metra M, Mullens W, Ribeiro ALP, Vaughn Y, Vest A; Joint American Heart Association (AHA)/American College of Cardiology (ACC)/European Society of Cardiology (ESC)/World Heart Federation (WHF) Task Force for the Universal Definition of Heart Failure in collaboration with the Heart Failure Society of America (HFSA), the Heart Failure Association (HFA) of the European Society of Cardiology, and the Japanese Heart Failure Society (JHFS)

Cell. 2026 Jun 25;189(13):3871-3882.e12. doi: 10.1016/j.cell.2026.06.002.
Baker DJ, Frommer LM, Uslu U, Patel KK, Zhu D, Engel NW, George JM, Zhao W, Kim SI, Sun L, Roselle C, Rommel PC, Young RM, Epstein JA, Hayat S, Arany Z, June CH

J Mol Neurosci. 2006;28(2):161-78. doi: 10.1385/JMN:28:2:161.
Sharma N, Brandis KA, Herrera SK, Johnson BE, Vaidya T, Shrestha R, Debburman SK

Med Trop Sante Int. 2023 Jul 3;3(3):mtsi.v3i3.2023.396. doi: 10.48327/mtsi.v3i3.2023.396. eCollection 2023 Sep 30.
Elien Gagnan Yan Zaou Tou RR, Mbaïkoua JM, Kosh Komba Palet JE, Guirou N

Nat Med. 2026 Jun 24. doi: 10.1038/s41591-026-04508-1.
Huang Z, Zeng L, Ruan Z, Zeng Q, Yan H, Jiang W, Xiong Y, Zhou C, Yang H, Liu L, Dai J, Zou N, Xu S, Wang Y, Wang Z, Deng J, Chen X, Wang J, Xiang H, Li X, Duchemann B, Chen G, Xia Y, Mok T, Scheiermann C, Lévi F, Yang N, Zhang Y

Cell. 2026 Jun 26:S0092-8674(26)00653-7. doi: 10.1016/j.cell.2026.06.004.
Chen S, Deng F, Peng B, Liu L, Wang J, Jin F, Xu J, Lin D, Chen W, Zhang D, Yi C, Zhang J, Zhong S, Zhu L, Huang Y, Yang J, Wang R, Sun X, Zhang Y, Ling Z, Ma L, Liu X, Sun B

Lancet. 2017 Dec 23;390(10114):2767. doi: 10.1016/S0140-6736(17)31954-2.
Levy A, Chargari C, Deutsch E, Rivera S

Nature. 2026 Jun 24. doi: 10.1038/s41586-026-10674-6.
Obermeyer Z, Schubert A, Ross J, Mullainathan S, Lingman M

WormBook. 2005 Jun 25:1-9. doi: 10.1895/wormbook.1.3.1.
Hodgkin J

J Am Coll Cardiol. 2026 Jun 29:S0735-1097(26)06703-3. doi: 10.1016/j.jacc.2026.05.036.
Walsh MN, Kober L, Sliwa K, Adamo M, Agarwal A, Banerjee A, Bozkurt B, Cikes M, Damasceno A, Desai AS, Felker GM, Hogan G, Kinugawa K, Kittleson M, Lam CSP, McDonagh T, Metra M, Mullens W, Ribeiro ALP, Vaughn Y, Vest A; Joint American Heart Association (AHA)/American College of Cardiology (ACC)/European Society of Cardiology (ESC)/World Heart Federation (WHF); Task Force for the Universal Definition of Heart Failure in collaboration with the Heart Failure Society of America (HFSA); Heart Failure Association (HFA) of the European Society of Cardiology, and the Japanese Heart Failure Society (JHFS)

J Am Vet Med Assoc. 2026 Jun 26:1-11. doi: 10.2460/javma.26.03.0170.
von Pfeil DJF, Adams RJ, Clark L, Dewey CW, Brunke MW, Garner M, Lanz OI, Miller N, Breshears L, Déjardin LM, Armitage A, Hayashi K, Vezzoni A

Hepatol Int. 2026 Jun 27. doi: 10.1007/s12072-026-11108-1.
You H, Maiwall R, Chen J, Ahn SH, Dokmeci K, Dou X, El-Sayed M, Fan JG, Gani R, Gao Z, George J, Ghazinian H, Goh G, Hamid S, Hou J, Huang SC, Ji D, Jia J, Kanda T, Kao JH, Kim YJ, Lesmana CRA, Mohamed R, Ning Q, Ormeci N, Otsuka M, Payawal D, Thuy PT, Sailey K, Sharma MK, Sollano JD, Sun J, Tanwandee T, Thompson A, Wang FS, Wang G, Wei L, Wong GLH, Wong VWS, Yeoh EK, Yip TC, Yu ML, Zhang W, Zhuang H, Lai CL, Omata M, Sarin SK, Lau G; APASL Viral Elimination Taskforce

Medicine (Baltimore). 2018 Apr;97(16):e0419. doi: 10.1097/MD.0000000000010419.
Owen GI, Pinto MP, Retamal IN, Fernádez MF, Cisternas B, Mondaca S, Sanchez C, Galindo H, Nervi B, Ibañez C, Acevedo F, Madrid J, Peña J, Bravo ML, Maturana MJ, Cordova-Delgado M, Romero D, de la Jara N, Torres J, Rodriguez-Fernandez M, Espinoza M, Balmaceda C, Freire M, Gárate-Calderón V, Crovari F, Jimenez-Fonseca P, Carmona-Bayonas A, Zwenger A, Armisen R, Corvalan AH, Garrido M

CA Cancer J Clin. 2026 Jul-Aug;76(4):e70094. doi: 10.3322/caac.70094.
Xiong J, Kwong YL, de Leval L, Qi SN, Ong CK, Gaulard P, Jaccard A, Horwitz SM, Li YX, Chen SJ, Suzuki R, Kim WS, Zhao WL